SYRE: Global trials of optimized biologic combinations in autoimmune diseases set up multiple late-stage catalysts
Focused on advancing optimized biologic combinations for autoimmune diseases, the company is running a global, near-phase III scale trial in IBD, with monotherapy and combination arms. Long-acting antibodies show efficacy and dosing advantages, and upcoming readouts in IBD, HS, and other indication…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.